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Abstract
Background: Hotspots are defined as the minimal functional domains involved in protein:protein
interactions and sufficient to induce a biological response.
Results: Here we describe the use of complex and high diversity phage display libraries to isolate
peptides (called Hotspot Ligands or HSPLs) which sub-divide the ligand binding domain of the
tumor necrosis factor receptor 2 (TNFR2; p75) into multiple hotspots. We have shown that these
libraries could generate HSPLs which not only subdivide hotspots on protein and non-protein
targets but act as agonists or antagonists. Using this approach, we generated peptides which were
specific for human TNFR2, could be competed by the natural ligands, TNFα and TNFβ and induced
an unexpected biological response in a TNFR2-specific manner.
Conclusions: To our knowledge, this is the first report describing the dissection of the TNFR2
into biologically active hotspots with the concomitant identification of a novel and unexpected
biological activity.
Background
Hotspots have been defined as the minimal functional
protein:protein interaction domains through which bio-
logical activity can be modulated [1–3]. A novel strategy
called Phenogenix® has been developed as a means for
studying these interactions. To enable Phenogenix®, we
use large and diverse phage display libraries consisting of
randomized 20 mer and 40 mer amino acid peptides with
> 1011 independent clones. Because of their ability to
modulate protein: protein interactions, the resulting pep-
tides are called Hotspot Ligands (HSPLs). Using this ap-
proach, we have successfully identified peptide agonists
and antagonists for a number of biologically important
molecules including growth hormone receptor, insulin re-
ceptor and the insulin-like growth factor receptor [2,3].
In this report, we describe the use of Phenogenix® to iden-
tify the critical protein:protein interactions underlying the
TNF/TNFR axis. TNFα and TNFβ have been extensively
studied and are involved in immune and pro-inflamma-
tory responses, playing an important role in host defenses
against infection and other disease states [4–7]. The bio-
logical effects of TNFα and TNFβ are mediated through
the two membrane associated receptors, TNFR1 (p55) and
TNFR2 (p75), that are expressed on the target cells [8,9].
The postulated pathogenic roles for TNF include sepsis
and other bacterial and viral pathologies [10–12], certain
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disorders such as rheumatoid arthritis [15,16], multiple
sclerosis [17] and Crohn's disease [18]. It is worth noting
that TNFα mutants have been identified that selectively
bind TNFR1. One such mutant induced less systemic tox-
icity yet showed no compromise in its anti-tumor activity
in nude mice [13]. These observations indicated that find-
ing modulators specific for each of the TNF receptors is in-
deed possible.
While TNFα binds equally well to both receptors, the ma-
jority of biologic responses attributed to TNF are mediat-
ed via TNFR1 although there is evidence that activation of
TNFR2 is responsible for some adverse effects of TNFα
[19–24]. Thus, the differential regulation of these two re-
ceptors may require drugs that specifically target either
TNFR1 or TNFR2 allowing therapeutic efficacy without
the expected toxicity profile. One obvious possibility then
is to search for Surrogates that selectively bind and regu-
late the individual receptors. To date several antagonistic
protein reagents have been isolated for treating diseases
with an underlying TNF etiology. These include neutraliz-
ing monoclonal antibodies and soluble forms of TNFR1
and TNFR2 [25–27]. However, both antibodies and extra-
cellular receptors are large proteins and not amenable to
oral administration. They also carry the unwanted risk of
stimulating an auto-immune response during chronic use.
By panning our peptide libraries against the TNFR2, we
isolated four HSPL peptides binding specifically to hu-
man TNFR2 that allow the subdivision of the receptor into
a minimum of at least three independent hotspots in-
volved in its interaction with TNFα. In a biological model
for TNFα activation of TNFR2, three of the four peptides
induced cytotoxic response in the target cell line suggest-
ing that at least one of these domains induced a unique
TNFR2-specific biological response. Overall, these data
show the utility of using the HSPL peptides for subdivid-
ing protein:protein interacting domains and for defining
unique novel biological activities not observed through
the natural ligand/receptor interaction.
Results
Human TNFR2 was panned with random 20 mer and 40
mer phage display peptide libraries of high diversity
[2,3,28]. After four rounds of panning, four phage clones
were isolated with specificity for TNFR2. The peptides
were initially divided into two groups: a 40 mer designat-
ed KcF12 and three 20 mers designated KcC7, KcD11 and
KcF6 (Table 1). From the amino acid sequences, KcC7,
KcD11 and KcF12 were found to have a pair of cysteine
residues suggesting the possibility of intra-chain disulfide
bonding. In addition, a putative motif, WxEYxxRGG, was
found for peptides KcF6 and KcD11 (Table 1). It was in-
teresting that this motif was related to a sequence Wx-
ExxxxxGG found at the C-terminal (amino acids 190–
198) of TNF-α. No appreciable sequence homology was
seen between either of the natural ligands, TNFα or TNFβ,
and KcF12 although the spacing of cysteine loop was close
to that seen in the cysteine rich domains of TNFR2 [29].
At present, it is not known whether these structural ele-
ments play a role in binding of the peptides to TNFR2 and
it may be that the peptides mimic rather than recapitulate
the contact domains of the natural ligands. ELISA analysis
showed that all four phage clones bound specifically to
human TNFR2 and did not react with either human or
murine TNFR1 or murine TNFR2 (data not shown).
Competition ELISAs were performed using TNFα and
TNFβ vs. the four phage clones at their ED50 values (Figure
1a,1b,1c,1d). More TNFα and TNFβ were required to
compete KcF12 than the other phage clones suggesting
that certain intrinsic properties of KcF12 (such as its
length and/or amino acid content) may contribute to a
higher relative affinity (Table 2). In addition, the synthetic
forms of KcC7, KcD11, KcF6 and the recombinant KcF12
(rKcF12) were able to compete the binding of TNFα and
TNFβ, as well as KcF6 and KcF12 phage clones in the mi-
cromolar range (unpublished data). Interestingly, the
three 20 mer HSPLs but not KcF12 were competed by an
anti-TNFR2 monoclonal antibody, mAb226, (Figure 2)
suggesting that KCF12 binds to a hotspot on TNFR2
distinct from the other 3 peptides. A summary of the
phage/peptide competition data is shown in Table 3.






The sequences shown are the deduced amino acid sequences of the human TNFR2-specific phage clones that were selective for TNFR2, but not 
TNFR1. The cysteine residues are underlined and highlighted in grey. A potential motif, WxEYxxRGG, found in peptides KcF6 and KcD11 are 
indicated as bolded one letter amino acid codes.Page 2 of 10
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and Jiyoye cells using a radioreceptor assay. Jurkat cells
have been reported to have approximately equal numbers
of TNFR1 and TNFR2 per cell [27] whereas Jiyoye cells ex-
press mainly TNFR2 (unpublished data). KcF12 inhibits
TNFα binding to Jiyoye cells with a Ki of about 2 uM
whereas the Ki for the peptide in Jurkat cells was found to
be >30 uM (Figure 3). Since TNFα binding to Jurkat prob-
ably involves both TNFR1 and TNFR2, the data offers ad-
ditional confirmation of KcF12's selectivity for TNFR2.
It has been previously reported that TNFα induced a
TNFR2-specific proliferation of the neuroblastoma cell
line SK-N-BE [30]. KcF12, KcC7 and KcF6 inhibited the
proliferative response to TNF-α in this cell line indicating
that they could act as antagonists (data not shown). In ad-
dition, the same three peptides were found to be cytotoxic
Figure 1
Competitive Displacement Of Phage Clones Expressing hTNFR2-Hotspot Peptide Ligands By Human TNF 
(Alpha And Beta) Or Soluble TNF Receptor (R1 Or R2) Fusions. Recombinant human TNFR2 was coated on Max-
iSorp 96 well plates and blocked with PBS containing 2% non-fat milk as previously described (3). Phage clones expressing 
Hotspot Peptide Ligands (phage clones at their ED50 values) are added in the presence of varying concentrations of competitor 
(e.g., TNF or soluble TNF receptor). Panel A) KcC7 phage competition, Panel B) KcD11 phage, Panel C) KcF6 phage, Panel D) 
KcF12 phage. IC50 values are determined by probing for phage binding (using HRP labeled anti-M13 antibody) to TNFR2 in the 
presence of competitor. Data is presented as percent inhibition and to determine binding kinetic parameters data were fit to a 
four-parameter logistic equation using Xlfit™, an add-in for Microsoft Excel.Page 3 of 10
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KcF12 possessed the strongest killing activity with an IC50
of ~700 nM whereas the IC50s for KcC7 and KcF6 were 2
uM and 7 uM, respectively. None of the peptides induced
a cytotoxic response in cell lines not expressing TNFR2
(data not shown). Interestingly, KcD11, which shares a
motif with KcF6 (Table 1), had no effect on SK-N-BE cells.
The absence of activity by KcD11 did not appear to be due
to breakdown of the peptide during culturing since mass
spectral analyses on aliquots retrieved from culture media
showed relatively no degradation of peptides between the
initial and the final time points (data not shown). There-
fore, the proliferation data suggests evidence of a hotspot
on TNFR2 recognized by KcF12, KcC7 and KcF6 that is
linked to this unique biological effect. The inhibition of
the KcC7 and KcF6 cytotoxic effect with mAb226 (Figure
4b) confirms the relationship between the peptide-in-
duced cytotoxic event and TNFR2 because of the anti-
body's specificity for TNFR2. Overall, these data indicate
Figure 2
Inhibition Of Hotspot Peptide Ligand(s) Binding To Recombinant Human Soluble TNFR2 By Anti-TNFR2 
Antibody, mAb226. HotSpot Peptide Ligand phage clones were added to 96 well plates with immobilized TNFR2 at a con-
centration which allowed 50% occupancy of receptor binding sites. Anti-TNFR2 antibody, mAb226, was added and serially 
diluted for competition. To visualize receptor bound HSPL-phage the reaction was probed with HRP labeled anti-M13 anti-
body. To demonstrate mAb226 interacted with the TNF binding pocket, TNF-alpha was added in a manner as described for 
the phage clones and TNF binding was determined using an anti-TNF antibody followed by HRP-anti-mouse IgG antibody. Data 
is presented as percent inhibition and were fit to a four-parameter logistic equation using Xlfit™, an add-in for Microsoft Excel.Page 4 of 10
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complex and may be composed of multiple hotspots ca-
pable of different regulatory functions.
Discussion
Peptide libraries have been successfully used for identify-
ing novel peptides mimicing natural molecules in terms
of the critical protein:protein interactions involved in bi-
ological activity. Yanofsky et al. [31] described a peptide
antagonist to IL-1 that was active in the nM range and
Wrighton et al. and Livnah et al. [32,33] identified pep-
tides binding to the erythropoietin (EPO) receptor with
full agonist activity in vivo. Neither the EPO agonist nor
the IL-1 antagonist peptides show any significant se-
quence homology to the natural ligand suggesting that
they act as mimics of the natural ligand. In the case of the
EPO agonists, X-ray crystallographic analysis revealed that
one of these peptides spontaneously formed non-covalent
homodimers that allowed the dimerization of two EPO
receptors. Two families of small peptides binding to the
human thrombopoietin receptor (TPOR) were isolated
that competed with the natural ligand TPO [34]. The pep-
tide with the highest affinity was subsequently dimerized
and shown to function as a potent TPO agonist in vivo. Re-
cently, a small, non-peptide organic molecule binding to
one chain of the EPO receptor was multimerized and
shown to mimic the biological activities of the EPO [35].
In this report we show that HSPLs can be isolated that
bind to human TNFR2 at its ligand-binding site and sub-
divide it into multiple hotspots. All of the peptides were
competed by both TNFα and TNFβ implying they recog-
nized a hotspot that mapped either within or at least over-
lapping the ligand-binding domain of TNFR2. The HSPLs
KcC7, KcD11, KcF6 but not KcF12 were also inhibited by
the neutralizing antibody mAb226 suggesting the 20 mers
but not KcF12 interact with a hotspot overlapping with
the one recognized by antibody. The fact that recom-
binant KcF12 peptide competed all of the phage expressed
peptides (Table 3) indicated that the four peptides also
recognize a common hotspot which may be the one re-
sponsible for TNF ligand binding to the receptor. In addi-
tion, the biological data suggests that KcD11 binds to a
hotspot that can be further separated from KcF12, KcF6
and KcC7. While we cannot rule out possible allosteric in-
teractions between the peptides, the data suggests that the
HSPLs were able to dissect the ligand-binding region of
TNFR2 into several structural and/or functional hotspots.
In addition, the HSPLs were specific for TNFR2 unlike the
native ligands TNF-α and TNF-β which bind to both re-
ceptors. These results demonstrate that the approach has
the ability to dissect critical protein:protein interaction
domains in terms of both structural and functional ele-
ments. Using a similar approach, we recently reported on
Table 2: Phage Competition ELISAs
Competitor IC50 (M)
Reporter Ligand hTNF-alpha hTNF-beta hTNFR1 hTNFR2
KcC7 phage 3.30E-12 6.29E-11 +/- 4.25E-08
KcD11 phage 1.14E-11 1.93E-11 +/- 2.08E-07
KcF6 phage 3.01E-11 7.93E-11 0 9.87E-09
KcF12 phage 2.60E-10 4.23E-10 +/- 4.17E-08
Phage-expressed HSPLs were added in the presence of varying concentrations of competitor (e.g., TNF ligands or soluble receptors). IC50s are 
determined by probing for phage binding to target in the presence of competitor.
Table 3: Summary Of HotSpot Ligand Interactions With TNFR2















KcF7 20 No + + + + + mAb226
KcD11 20 Yes + + + - - NA
KcF6 20 Yes + + + + + mAb226
KcF12 40 No + + - + + KcD11
NA: Not applicablePage 5 of 10
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Hotspot Peptide Ligand Kcf12 Competes TNF Binding To Endogenous TNFR2 Receptors. The data are from rep-
resentative TNFα and KcF12 competition experiments in Jurkat and Jiyoye cells. The binding of TNFα to TNFR2 on intact cells 
was measured in a radio-receptor assay using Jurkat and Jiyoye cells and the MultiSreen™ assay filter plate system as described 
[39]. Data analysis was performed with an add-in for Microsoft Excel, Xlfit™ (ID Business Solutions, Guildford, UK), which 
allows curve fitting using nonlinear regression. To determine binding kinetic parameters, the four-parameter logistic equation y 
= Bottom + (Top – Bottom)/(1 + (IC50/x)Hill slope) was used to calculate IC50 values and Hill slopes. Ki values were calculated 
according to the equation, Ki = IC50/(1 + [ligand]/Kd). Data from replicate experiments in Jurkat cells (upper panel) yielded 
IC50 value of 1.64 ± 0.62 × 10-9 M (mean ± SD, n = 4) with a Hill slope of -0.66 ± 0.07 for TNF-alpha. Data from replicate 
experiments in Jiyoye cells (lower panel) yielded IC50 value of 2.28 ± 0.96 × 10-10 M (mean ± SD, n = 4) with a Hill slope of -
0.52 ± 0.03 for TNF-alpha. Data from replicate experiments in Jiyoye cells (lower panel) yielded IC50 values of 3.56 ± 0.35 × 
10-6 M (mean ± SD, n = 4) for HotSpot TNFR2 peptide KcF12.Page 6 of 10
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Cytotoxic Effect induced By The HotSpot Peptide Ligands In SK-N-BE Cells. SK-N-BE cells were seeded in 96 well 
plates using SK-N-BE medium and allowed to grow to 75–80% confluency. Cells were starved overnight in media containing 1% 
serum before each cell experiment. Briefly, cells were first treated with a TNFR1 specific receptor blocking antibody, mAb225 
(10 µg/mL), for at least 30 min at 37°C prior to the addition of test agents. All agents used in the cell-based experiments were 
serially diluted and mixed in a separate 96 well plate before transferring into the 96 well plate containing SK-N-BE cells. Cells 
were then returned into the incubator for 40–45 hrs before the addition of 0.1 vol. of WST-1 (Roche Diagnostics Corpora-
tion, Indianapolis, IN) to quantitate cell number. The plates were further incubated and developed according to the manufac-
turer's instruction. Panel A) Synthetic HotSpot peptide ligands, KcF12, KcC7, and KcF6 act as inverse agonists by inhibiting 
TNFR2-linked cellular survival in SK-N-BE cells. TNF-alpha causes cellular proliferation via a TNFR2-linked mechanism in SK-
N-BE cells. Addition of a control peptide with a non-relevant sequence does not alter cell survival. Panel B) Blockade of TNFR2 
binding pocket by Anti-TNFR2 antibody, mAb226, inhibits the cytotoxic action of KcC7 and KcF6, but not KcF12. Peptides 
were added at their ED80 values while mAb226 was at 10 µg/mL. IC80 (10 µM) concentrations, while KcD11 was added at 
either 10 µM or 100 µM.Page 7 of 10
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sulin receptor into two separate and non-overlapping
hotspots with different biological activities [3].
It has been shown that TNFα induced proliferation of the
undifferentiated neuroblastoma cell line, SK-N-BE, result-
ed from activation of TNFR2 [30]. Proliferation of SK-N-
BE cells could be suppressed by the pre-incubation of cells
with anti-TNFR2 blocking antibodies without concomi-
tant cytotoxicity (data not shown). While all of the pep-
tides blocked the agonist effects of TNFα indicating that
they can act as antagonists, KcC7, KcF6 and KcF12 by
themselves induced a cytotoxic response by killing SK-N-
BE cells in the absence of TNFα. This is surprising because
these peptides share a hotspot with the natural ligand
TNFα (which is proliferative rather than-cytotoxic) and
KcC7 and KcF6 bind to a hotspot common to the
neutralizing but non-cytotoxic, antibody mAb226. Over-
all, these data suggest that activation (agonism or cytotox-
icity) of TNFR2 is mediated through unique hotspots on
the receptor that can be defined by the peptides. Under
the present experimental conditions, it is unclear whether
the natural ligand, TNFα, touches the hotspot responsible
for cytotoxicity although one can speculate that, if it does,
the cytotoxic effect might be nullified by the sum of the
natural ligand:receptor interactions. Competition experi-
ments showing that mAb 226 reversed the effects of KcC7
and KcF6 confirm that these two peptides induce their ef-
fects though their interaction with TNFR2. These findings
suggest that TNFR2 has multiple biological functions. In
addition to transferring TNFα to TNFR1 as proposed by
the ligand passing model [36], TNFR2 may have a role in
modulating proliferative responses in both positive and
negative manner. Ongoing studies will attempt to eluci-
date the mechanism of action behind the phenomenon
such as the effects on downstream signaling pathways in-
cluding NFkB, and apoptosis. However, it is possible that
peptide-induced cytotoxicity works through a mechanism
similar to TNF mediated apoptosis in T-cells [37].
Conclusions
In summary, HSPLs were isolated with which we were
able to dissect the ligand-binding domain of a natural re-
ceptor and generate information about novel and unex-
pected bioactivities. This technology has also been
successfully used for known protein targets, such as the in-
sulin receptor [3] and TNF-β [38] as well as non-protein
targets such as disease-specific RNAs [38]. We have also
shown that the HSPL libraries identify hotspots on novel
genes of unknown function and identify functional inter-
action pathways (manuscript in preparation). Overall, the
use of HSPLs have the potential to become a general




E. coli, strain TG1 (genotype = K12∆(lac-pro), supE, thi,
hsd∆5/F' [traD36, proAB, lacIq, lacZ∆M15]) was obtained
from Pharmacia (Piscataway, NJ). Recombinant human
Tumor Necrosis Factor-α (rhTNFα) was purchased from
R&D Systems, Inc. (Minneapolis, MN) or PeproTech Inc.
(Rocky Hill, NJ). Monoclonal antibodies against recom-
binant human soluble TNF receptor RI (mAb225) and RII
(mAb226) were purchased from R&D Systems, Inc. (Min-
neapolis, MN). WST-1 was purchased from Roche (Nut-
ley, NJ). 125I-TNFα (NEX 257) with a specific activity of
97 µCi/µg (1698 Ci/mmol) was purchased from NEN Life
Science Products, Inc (Boston, MA). Beckman Ready Safe™
scintillation fluid was purchased from Beckman Coulter,
Inc. (Fullerton, CA). MultiSreen™ assay filter plate system
and 96-well MultiScreen® MAFC filter plates were from
Millipore (Bedford, MA). RPMI 1640 media, fetal bovine
serum, and GlutaMAX™-I were obtained from Life
Technologies (Rockville, MD). Polyvinylpyrrolidone
(PVP), Tween-20R™, phosphate-buffered saline (PBS),
and Dulbecco's phosphate-buffered saline (containing no
calcium or magnesium) were purchased from Sigma
Chemical Co. (St. Louis, MO). All other chemicals and re-
agents used were analytical grade.
Cell Culture
SK-N-BE neuroblastoma cells, Jurkat (TIB-152) and Jiyoye
(CCL-87) cells were obtained from the ATCC (Manassas,
VA). SK-N-BE and Jurkat cells were maintained in RPMI
1640 media supplemented with 10% fetal bovine serum
(FBS) and 2 mM GlutaMAX™-I, while Jiyoye cells were
maintained in RPMI 1640 media supplemented with 15%
FBS and 2 mM GlutaMAX™.
Design of the Primary Peptide Libraries
A description of library design and production has been
previously published [3,28].
Subtractive Panning and ELISA
Panning was done as described [3,28], except that only 6
wells of a 96-well microtiter plate were coated with target
at concentrations ranging from 10–100 ng/well. The cross
reactive phages from the eluted phage were then subtract-
ed by panning sequentially against human TNFR1, TNFα
and TNFβ as a way to obtain peptides specific to the orig-
inal target. ELISA was done as previous described [3,28].
Phage Competition ELISA Studies
Target was coated on MaxiSorp plates and blocked with
NFM-PBS as described [3,28]. HSPLs (phage clones or
synthetic peptides) are added in the presence of varying
concentrations of competitor (e.g., TNF ligand or soluble
receptor). IC50s are determined by probing for phage or
peptide binding to target in the presence of competitor.Page 8 of 10
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The binding of TNFα to TNFR2 on intact cells was meas-
ured in a radioareceptor assay using Jurkat and Jiyoye cells
and the MultiSreen™ assay filter plate system as described
[39]. Data analysis was performed with an add-in for Mi-
crosoft Excel, Xlfit™ (version 2.0) from ID Business
Solutions (Guildford, UK), which allows curve fitting us-
ing nonlinear regression. To determine binding kinetic
parameters, the Four-Parameter logistic equation y = Bot-
tom + (Top – Bottom)/(1 + (IC50/x)Hill slope) was used to
calculate IC50 values and Hill slopes. Ki values were calcu-
lated according to the equation, Ki = IC50/(1 + [ligand]/
Kd), as described by Cheng and Prusoff [40].
Proliferation cell assay
SK-N-BE cells were seeded loosely in 96 well plates in SK-
N-BE medium and allowed to grow to 75–80% confluen-
cy. Cells were starved overnight in media containing 1%
serum before each cell experiment. Briefly, cells were first
treated with a human TNFR1 blocking mAb, mAb225 (10
ug/ml), for at least 30 min at 37 C prior to the addition of
agents. All agents used in the cell experiment were serial
diluted at 1:2 and mixed in a separate plate before trans-
ferring into the actual cell plate. The starting highest final
concentration of each peptide was at 30 uM or at its high-
est possible concentration. Cells were then returned into
the incubator for 40–45 hrs before the addition of 1/10
vol of WST-1. The plates were further incubated and devel-
oped according to the manufacturer's instruction.
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